Tag: UAMS

News

A New Approach to Overcome Immunotherapy Resistance 

Newly granted patent: U.S. Patent No. 12,268,674 B2, “Mi-2β Inhibitor as an Immunotherapy Agent”  What’s the problem?  Immune checkpoint therapies, such as anti-PD-1 antibodies (e.g. Keytruda, Opdivo), have transformed cancer treatment. Yet many patients either don’t respond at all or eventually develop resistance. This limits their long-term effectiveness, leaving a major gap in oncology care.  What does this technology do?  This patent covers novel small-molecule inhibitors that block the ATPase pocket of Mi-2β (CHD4), a chromatin remodeling protein identified as a key driver of PD-1 resistance.  One lead compound, Z36-MP5, restores responsiveness to PD-1 therapy by:  By directly targeting tumor-intrinsic resistance mechanisms, Mi-2β inhibitors open the door to a first-in-class therapeutic strategy to make immunotherapy work for more patients. 

Read More »
Events

BioVentures to Participate in the TRI Research Expo 2025 

BioVentures will be present at the Translational Research Institute (TRI) Research Expo 2025, taking place Wednesday, September 10, from 4:00 to 6:00 p.m. CDT at the Reynolds Institute on Aging, First Floor.  The Expo brings together more than 50 research services across UAMS, providing investigators with the opportunity to explore resources, build connections, and learn about available support for advancing their work. Visitors can stop by the BioVentures table to discuss invention disclosures, licensing, commercialization pathways, and opportunities to bring biomedical innovations to market.  Don’t miss the chance to connect with colleagues, enjoy refreshments, and learn how BioVentures can support your research journey.  👉 Register here

Read More »
Blog

From Disclosure to Market: How the BioVentures Process Works 

Curious how an idea becomes a protected invention at UAMS?  At BioVentures, we guide innovators through every step, from disclosure to patent decisions and market strategy. Here’s how the process works, what to expect, and how we support you along the way. 1) Submit Your Invention Disclosure  The first step is fully and adequately disclosing your invention to BioVentures by submitting an invention disclosure. Even if you’ve already reached out to schedule a meeting, we require a disclosure to initiate the process. It allows us to review the technology in advance, and gather essential information on compliance, funding, and inventorship.  We’ve recently adopted a new AI-powered disclosure platform to simplify the process. You can upload relevant documents—papers, figures, posters, presentations—and the system will generate a draft disclosure for you to review and edit before submission:  👉 Submit your disclosure  The form captures a complete overview of your invention, its potential applications, and any existing data or prototypes. Once submitted, BioVentures typically reviews the disclosure within 1–2 weeks before scheduling a meeting with you.  Typical timing: BioVentures review in 1–2 weeks.  2) Meeting with the Technology Manager  We meet with the inventor to clarify the technology, confirm federal compliance needs, capture inventor and funding information, and discuss long‑term goals and commercialization paths.  Typical timing: Scheduled within 1–2 weeks after disclosure review.  3) P&CC Decision (Patent & Copyright Committee)  The inventor presents at the P&CC. This committee reviews the presented technology and makes a determination on how the technology should be protected. Outcomes can include:  Typical timing: P&CC is usually scheduled 1–2 months after acceptance of the disclosure.  4) Protection Strategy Based on P&CC Outcome  The legal protection route follows the P&CC decision. If a provisional patent filing is recommended, we move quickly to secure a priority date and a 12‑month window to strengthen data and assess market potential. This is because in the United States is a first to file country which means that the right to a patent generally belongs to whichever inventor files an application with the USPTO first, not to whoever first conceives the idea. As such, protecting your invention in a timely manner is important to us.   Typical timing: Provisional filing is typically completed within a few weeks of the P&CC meeting.  5) Marketing and Commercial Pathways  If the inventor agrees, we begin targeted outreach. Options include:  Why Early Disclosure Matters  Submitting your invention disclosure early is essential. It helps preserve your patent rights before any public disclosure or publication, ensuring your ability to pursue protection. Early disclosure also allows BioVentures to align your IP strategy with funding sources and compliance requirements, and accelerates our ability to evaluate the market potential and identify relevant partners.  This overview is for general information and does not constitute legal advice. Specific strategies and timelines may vary by technology.  Have an invention to disclose? Submit your disclosure now!

Read More »
Blog

BioVentures Supports UAMS M1 Students in PCAR Summer Program

BioVentures supported University of Arkansas for Medical Sciences (UAMS) first-year medical students this summer through the Partnership in Cancer Research (PCAR) program. Over eight weeks, participants worked in multidisciplinary teams to address real-world challenges in cancer prevention, diagnosis, treatment, or survivorship. The program culminated in entrepreneurial pitch presentations to a panel of judges. Three BioVentures team members served as mentors, advising students on refining problem statements, assessing market opportunities, and developing business models. Another team member participated as a judge, providing feedback from a commercialization perspective. The collaboration aimed to foster entrepreneurial thinking, highlight the role of innovation in cancer care, and encourage future clinician-innovators at UAMS. This initiative reflects BioVentures’ ongoing commitment to advancing healthcare entrepreneurship and translating research into real-world impact.

Read More »
News

A New Antibody Detects a Hidden Cancer Signal 

Newly granted patent: U.S. Patent No. 12,281,171 B2, “Periostin Antibodies and Methods of Using the Same” What’s the problem? Some cancers create a unique “signal” by adding a rare sugar modification to proteins like periostin. This tumor-specific marker could help identify and target cancer, but it’s extremely difficult to detect. Traditional tools often miss it because these sugar structures are hard for the immune system to recognize.  What does this technology do? This patent covers a new monoclonal antibody, C9, that targets the sugar marker not the whole protein. Using samples from ovarian cancer patients, inventors at UAMS identified an antibody that binds precisely to this cancer-specific structure. In mouse models, this C9 antibody successfully located and attached to tumors, showing strong potential for cancer imaging and targeted treatment. 

Read More »
Blog

Innovation Week Opens in 7 Days — Are You Registered?

In one week, BioVentures will welcome innovators from across UAMS and beyond for Innovation Week 2025. Four days of ideas, insight and industry connection on the UAMS Main Campus in Little Rock. Whether you’re advancing breakthrough research, launching a startup or simply curious about commercialization, this is the place to turn discovery into opportunity. Date Time Location Highlight Mon 12 8 – 10 a.m. Biomed I Atrium Meet & Greet: coffee, donuts and conversation with the BioVentures team Tue 13 11:30 a.m. I. Dodd Wilson 115 A/B Inventors Lunch & Award Ceremony — celebrating UAMS discoveries Wed 14 Noon Cancer Institute, Strauss‑McCaskill Learning Center “Raising Capital for Your Startup Endeavors” with Michael Geranen Thu 15 10 a.m. – 6 p.m. I. Dodd Wilson Industry‑Research Forum — keynote by Justin Rerko, expert panels, lunch & networking happy hour Full agenda details, speaker bios and session descriptions are available on the registration page. Why Attend? Seats are limited. See you next week at Innovation Week 2025 — Where Discovery Meets Opportunity.

Read More »
Events

BioVentures Innovation Week to Celebrate Innovation & Entrepreneurship at UAMS 

BioVentures invites the UAMS community to Innovation Week, May 12-15, 2025.  Designed to showcase innovation, foster industry connections and highlight the pathway from research to commercialization, Innovation Week offers opportunities for everyone from seasoned inventors and those just starting out.  Whether you’re an entrepreneur, inventor, researcher or industry partner, Innovation Week is your chance to engage with the thriving healthcare innovation ecosystem at UAMS and beyond.  Innovation Week Highlights  Join us to learn, connect and take your ideas to the next level.   Learn more & register.

Read More »
Education

From Idea to Impact: How IP Powers Public Good

Join us at 2 p.m. Wednesday, Oct. 16, for Health Sciences Entrepreneurship Grand Rounds, featuring Eric Peterson, Ph.D., BioVentures LLC interim president, at the Winthrop P. Rockefeller Cancer Institute, Betsy Blass Conference Room, 10th Floor. In this session, “From Idea to Impact: How IP Powers Public Good,” Peterson will explore the pivotal role of intellectual property in driving public benefit.

Read More »
News

BioVentures Receives $2.4 Million Grant to Address Maternal, Infant Deaths 

BioVentures LLC will receive up to $2.4 million over the next four years to test prevention strategies for reducing high rates of maternal and infant deaths in the Arkansas Delta.   The grant from the U.S. Department of Health and Human Services (HHS) will fund a combination of education, training, outreach and preventive health services focusing on Helena-West Helena, Lake Village and Pine Bluff. The initial $599,887 grant is for one year and must be renewed each year.  The grant is a collaborative mission between BioVentures LLC, the Institute for Digital Health & Innovation (IDHI), and the Division for Academic Pathways and Workforce Partnerships (DAPWP) at UAMS. “This is a big team effort, and the HHS grant will help us address one of the most significant, preventable health issues in our state,” said Stefanie Kennon-McGill, Ph.D., the grant’s principal investigator and project director, as well as senior program manager for BioVentures, which is the project’s operations manager.   Kennon-McGill noted that while BioVentures is better known to the UAMS campus for its mission to help UAMS researchers protect and transfer their discoveries to the public, its reach has expanded in recent years to find other innovative ways to improve the health of Arkansans. (The ACTIVE program is another key example).  “The mission at BioVentures has always included a commitment to growing the Arkansas economy, especially in the field of healthcare and health technology,” said Eric Peterson, Ph.D., BioVentures interim president. “We are proud to contribute to the economic development of the state, as well as the advancement of health for all Arkansans, through these new programs that reach beyond the walls of UAMS and to impact individuals where they live in communities across the state.”  As of March 2024, Arkansas had the highest maternal mortality rate in the United States, at 8.6 deaths per 100,000 live births, compared to the national average of 5.4. Arkansas also has the third highest infant mortality rate in the United States, with 7.67 infant deaths per 1,000 live births, based on 2022 data.   “Our goal with this grant is to test innovative, sustainable strategies to prevent maternal and infant deaths in the Delta region, where Black women are 1.8 times more likely to have pregnancy-related deaths than white, non-Hispanic women,” Kennon-McGill said.   Called the Delta Maternal Outreach and Transformational Health Education Resource (Delta MOTHER) project, it will establish and track community-level health initiatives. The primary activities supported by the grant will include:    The Institute for Digital Health & Innovation and its High-Risk Pregnancy Program will offer the Delta MOTHER project clinical expertise, partnership connectivity and fiscal management. Its contributions also include access to its three grant-funded satellite digital health resource centers at Lake Village, Helena-West Helena and Pine Bluff. The institute’s mission includes seeking to eliminate health care disparities in Arkansas and beyond through digital health and health care innovations.  The Division for Academic Pathways and Workforce Partnerships will engage HBCU students through its Serving Underrepresented Populations through Engagement and Research (SUPER) Program. The SUPER Program provides opportunities for undergraduates to conduct community-based research, focusing on health disparities that affect medically underserved populations. It is a component of the HBCU Med Track Program.   Other key partners on the grant are the Jefferson Regional Medical Center School of Nursing in Pine Bluff, the Arkansas Rural Health Partnership in Lake Village, and UAMS East Regional Campus in Helena-West Helena. 

Read More »